Aphasia-specific or generic outcomes? a comparison of two health-related quality of life instruments for economic evaluations of aphasia treatments

失语症特异性疗效还是通用疗效?两种健康相关生活质量评估工具在失语症治疗经济评价中的比较

阅读:1

Abstract

PURPOSE: Economic evaluations based on health-related quality of life (HRQOL) inform healthcare decisions. The generic EuroQol 5-Dimensions Health Questionnaire, 3-Level (EQ-5D-3L) permits conversion to utility values required for economic evaluations but is not validated for people with aphasia. The aphasia-specific Stroke and Aphasia Quality of Life Scale-39 g (SAQOL-39g) measures HRQOL, however, cannot be used to generate utility values. This study aimed to compare the performance of these two instruments. METHODS: HRQOL was rated at baseline and 12 weeks in participants of the Constraint Induced or Multi-Modal Personalised Aphasia Rehabilitation (COMPARE) randomised controlled trial. We assessed: (1) distribution of self-rated HRQOL scores, (2) convergent validity between EQ-5D-3L (domains; utility values; visual analogue scale) and SAQOL-39g (domain scores; total mean scores) using Spearman's correlations, (3) Construct validity through exploratory factor analysis, and (4) discriminative ability of converted EQ-5D-3L utilities in measuring compromised HRQOL (SAQOL-39g scores ≤ 4). RESULTS: Participants (n = 201 baseline, n = 190 12 weeks) completed both instruments (69% male, median age 63.6 years, median time since stroke 2.5 years). Ceiling effects were high for the EQ-5D-3L at baseline (45-79%) versus the SAQOL-39g (0-6%). Convergent validity between the SAQOL-39g communication domain and the EQ-5D-3L (r = 0.04-0.28) was weak at both time points. Factor analysis revealed distinct underlying constructs between instruments. EQ-5D-3L utility scores demonstrated reasonable performance (0.80 baseline; 0.78 12-weeks) in measuring poor HRQOL. CONCLUSION: Our findings suggest that EQ-5D-3L use in economic evaluations including people with aphasia requires caution. Alternative HRQOL instruments require evaluation to ensure fair prioritisation of aphasia treatments.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。